エピソード

  • Unlocking the Power of IL-2 with Aulos CEO, Aron Knickerbocker

    Unlocking the Power of IL-2 with Aulos CEO, Aron Knickerbocker
    2024/09/18
    Immunotherapies continue to redefine treatment for many types of cancer and one of the first immunotherapies approved and used clinically as a therapeutic is Interleukin-2, or IL-2. Aulos Bioscience is an immuno-oncology company that has developed AU-007, a potential best-in-class IL-2, that improves on many of the other IL-2 products in development. In this episode, we discuss the promise of AU-007 with President and CEO, Aron Knickerbocker. Link to Interleukin-2 review article can be found here: https://www.nature.com/articles/s41587-022-01390-3
    続きを読む 一部表示
    38 分
  • Left Behind: Addressing Health Equity for the Rare Disease Patient Community

    Left Behind: Addressing Health Equity for the Rare Disease Patient Community
    2024/09/09
    In this podcast episode, we discuss the importance of addressing health equity for the rare disease community with Tamar Thompson, Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease. Tamar discussed her efforts to champion health policy, advocacy, equity, and awareness for rare diseases. Link to NMOSD video mentioned in episode: https://www.youtube.com/playlist?list=PLJQx_6LtucSB9GGeiWTycLm7wjK_LX0ZI
    続きを読む 一部表示
    21 分
  • Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

    Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD
    2024/09/05
    In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma. Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.
    続きを読む 一部表示
    30 分
  • Unlocking AI In Oncology with James Zou, PhD

    Unlocking AI In Oncology with James Zou, PhD
    2024/08/27
    In this podcast episode, Dr. James Zou, Associate Professor of Biomedical Data Science and Faculty DIrector of the AI for Health department at Stanford University, shares current use cases for AI in healthcare and oncology and discusses how we can overcome challenges with LLMs to unlock the full potential of AI.
    続きを読む 一部表示
    25 分
  • Revolutioning Patient Access: An Interview with Genoplex CTO, Shoukri Kattan

    Revolutioning Patient Access: An Interview with Genoplex CTO, Shoukri Kattan
    2024/08/22
    In this episode, Genoplex Founder and CEO, Chris Leidli, and CTO, Shoukri Kattan, take a dive deep into their shared passion for health, wellness, and longevity, and explore how technology is revolutionizing patient access to advanced therapies. Chris and Shoukri discuss the groundbreaking work happening at Genoplex, including how the company's Advanced Therapy Connect digital platform is transforming the way patients connect with life-changing treatments.
    続きを読む 一部表示
    44 分
  • Building a Leading Cell Therapy Service Line with Robb Richards - Penn Medicine

    Building a Leading Cell Therapy Service Line with Robb Richards - Penn Medicine
    2024/08/14
    Our guest for this podcast episode is Robb Richards, Corporate Director of Cell Therapy and Transplant at University of Pennsylvania, Penn Medicine. In this episode, we discuss how Penn Medicine is working to improve patient access to cellular therapies and how technology has evolved to streamline operational and clinical workflows to enhance patient experience.
    続きを読む 一部表示
    25 分
  • How MedStack helps Health Tech companies with Compliance and Data Privacy

    How MedStack helps Health Tech companies with Compliance and Data Privacy
    2024/07/28
    Our guest for this episode is Balaji Gopalan, CEO and Co-Founder of MedStack where we discuss how MedStack's tech stack is enabling digital health start-ups to be healthcare data compliant. MedStack streamlines compliance with out-of-the-box HIPAA controls and ready-to-use privacy policies, enabling the faster and more cost-effective development of digital health applications. With built-in security controls and third-party validation, MedStack is setting new standards in healthcare technology.
    続きを読む 一部表示
    41 分
  • How NervGen is Developing Novel Treatments to Repair Damage to the Nervous System

    How NervGen is Developing Novel Treatments to Repair Damage to the Nervous System
    2024/07/09
    Our guest for this podcast episode is Mike Kelly, President & CEO of NervGen Pharma. NervGen is a clinical-stage biotech company at the forefront of developing treatments that empower the nervous system to repair itself following damage from injury or disease.
    続きを読む 一部表示
    20 分